对 Plöderl 等人关于 "艾司西酞普兰治疗儿童和青少年广泛性焦虑症的多中心双盲安慰剂对照试验 "的答复。

IF 1.5 4区医学 Q2 PEDIATRICS

Journal of child and adolescent psychopharmacology Pub Date : 2024-03-01 Epub Date: 2024-01-16 DOI:10.1089/cap.2023.0089

Jeffrey R Strawn, Jeffrey A Mills

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Response to Plöderl et al. re: "A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder".

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of child and adolescent psychopharmacology 医学-精神病学

CiteScore

3.60

自引率

5.30%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Child and Adolescent Psychopharmacology (JCAP) is the premier peer-reviewed journal covering the clinical aspects of treating this patient population with psychotropic medications including side effects and interactions, standard doses, and research on new and existing medications. The Journal includes information on related areas of medical sciences such as advances in developmental pharmacokinetics, developmental neuroscience, metabolism, nutrition, molecular genetics, and more. Journal of Child and Adolescent Psychopharmacology coverage includes: New drugs and treatment strategies including the use of psycho-stimulants, selective serotonin reuptake inhibitors, mood stabilizers, and atypical antipsychotics New developments in the diagnosis and treatment of ADHD, anxiety disorders, schizophrenia, autism spectrum disorders, bipolar disorder, eating disorders, along with other disorders Reports of common and rare Treatment Emergent Adverse Events (TEAEs) including: hyperprolactinemia, galactorrhea, weight gain/loss, metabolic syndrome, dyslipidemia, switching phenomena, sudden death, and the potential increase of suicide. Outcomes research.